New Questions About Contralateral Breast Cancer, Help for Brain Metastases

IMPORTANCE: The benefit of bilateral mastectomy for women with unilateral breast cancer in terms of deaths from breast cancer has not been shown. ͏    ͏    ͏    ͏    ͏    ͏    ͏    ͏    [SYNOPSI logo] [Dr image] Rosana Gnanajothy, MD Breast Medical Oncologist Hematology Oncology Physician Friday, September 13, 2024 New findings question the metastatic potential of contralateral breast cancer, as well as the long-held belief that the contralateral tumor is a new primary breast cancer. Also, neratinib plus T-DM1 helped combat brain metastases in HER2+ breast cancer, including patients with prior T-DM1 exposure. The HER2DX genomic assay predicted pathological complete response in patients on neoadjuvant trastuzumab and pertuzumab (with or without chemotherapy) and ID'd patients at higher risk of recurrence. Plus:Â important news from a negative study showing that adding ipatasertib to paclitaxel did not improve outcomes in metastatic triple-negative breast cancer patients with PIK3CA/AKT1/PTEN alterations. JAMA Oncology [Bilateral Mastectomy and Breast Cancer Mortality.]( Annals of Oncology [Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.]( Neuro-Oncology [FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases.]( Clinical Cancer Research [HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.]( Clinical Cancer Research [Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.]( [A Property of Everyday Health group] © 2024 Everyday Health Media, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=Non Sold MPT Condition Alert_Oncology) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011